BH Harvey
Cited by
Cited by
The nature of relapse in schizophrenia
R Emsley, B Chiliza, L Asmal, BH Harvey
BMC psychiatry 13, 1-8, 2013
Stress–restress evokes sustained iNOS activity and altered GABA levels and NMDA receptors in rat hippocampus
BH Harvey, F Oosthuizen, L Brand, G Wegener, DJ Stein
Psychopharmacology 175, 494-502, 2004
Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity
G Wegener, V Volke, BH Harvey, R Rosenberg
Brain research 959 (1), 128-134, 2003
Social isolation rearing induces mitochondrial, immunological, neurochemical and behavioural deficits in rats, and is reversed by clozapine or N-acetyl cysteine
M Möller, JL Du Preez, FP Viljoen, M Berk, R Emsley, BH Harvey
Brain, behavior, and immunity 30, 156-167, 2013
Neuroprogression in schizophrenia: pathways underpinning clinical staging and therapeutic corollaries
J Davis, S Moylan, BH Harvey, M Maes, M Berk
Australian & New Zealand Journal of Psychiatry 48 (6), 512-529, 2014
Cortical/hippocampal monoamines, HPA-axis changes and aversive behavior following stress and restress in an animal model of post-traumatic stress disorder
BH Harvey, L Brand, Z Jeeva, DJ Stein
Physiology & behavior 87 (5), 881-890, 2006
Endocrine, cognitive and hippocampal/cortical 5HT1A/2A receptor changes evoked by a time-dependent sensitisation (TDS) stress model in rats
BH Harvey, C Naciti, L Brand, DJ Stein
Brain research 983 (1-2), 97-107, 2003
Animal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacology
S Korff, BH Harvey
Psychiatric Clinics 29 (2), 371-390, 2006
Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors
BH Harvey, CD Bouwer
Clinical neuropharmacology 23 (2), 90-97, 2000
Isolation rearing-induced deficits in sensorimotor gating and social interaction in rats are related to cortico-striatal oxidative stress, and reversed by sub-chronic clozapine …
M Möller, JL Du Preez, R Emsley, BH Harvey
European Neuropsychopharmacology 21 (6), 471-483, 2011
Azure B, a metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase
A Petzer, BH Harvey, G Wegener, JP Petzer
Toxicology and applied pharmacology 258 (3), 403-409, 2012
A critical inquiry into marble-burying as a preclinical screening paradigm of relevance for anxiety and obsessive–compulsive disorder: Mapping the way forward
G De Brouwer, A Fick, BH Harvey, DW Wolmarans
Cognitive, Affective, & Behavioral Neuroscience 19, 1-39, 2019
Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram
PD Carey, J Warwick, DJH Niehaus, G Van der Linden, BB Van Heerden, ...
BMC psychiatry 4 (1), 1-8, 2004
A high-fat diet exacerbates depressive-like behavior in the Flinders Sensitive Line (FSL) rat, a genetic model of depression
A Abildgaard, L Solskov, V Volke, BH Harvey, S Lund, G Wegener
Psychoneuroendocrinology 36 (5), 623-633, 2011
Recent advances in drug action and therapeutics: relevance of novel concepts in G‐protein‐coupled receptor and signal transduction pharmacology
CB Brink, BH Harvey, J Bodenstein, DP Venter, DW Oliver
British journal of clinical pharmacology 57 (4), 373-387, 2004
Metabotropic and ionotropic glutamate receptors as neurobiological targets in anxiety and stress-related disorders: focus on pharmacology and preclinical translational models
BH Harvey, M Shahid
Pharmacology Biochemistry and Behavior 100 (4), 775-800, 2012
Neurobiology of antidepressant withdrawal: implications for the longitudinal outcome of depression
BH Harvey, BS McEwen, DJ Stein
Biological Psychiatry 54 (10), 1105-1117, 2003
Stereotypic behaviour in the deer mouse: pharmacological validation and relevance for obsessive compulsive disorder
S Korff, DJ Stein, BH Harvey
Progress in Neuro-Psychopharmacology and Biological Psychiatry 32 (2), 348-355, 2008
A review of biomarkers in mood and psychotic disorders: A dissection of clinical vs. preclinical correlates
S Brand, M Möller, B Harvey
Current Neuropharmacology 13 (3), 324-368, 2015
The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment
EJ van Vuren, SF Steyn, CB Brink, M Möller, FP Viljoen, BH Harvey
Biomedicine & Pharmacotherapy 135, 111200, 2021
The system can't perform the operation now. Try again later.
Articles 1–20